Compare FINV & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINV | FTRE |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2017 | 2023 |
| Metric | FINV | FTRE |
|---|---|---|
| Price | $4.87 | $16.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $12.10 | ★ $14.06 |
| AVG Volume (30 Days) | 1.1M | ★ 1.1M |
| Earning Date | 05-19-2026 | 05-05-2026 |
| Dividend Yield | ★ 6.09% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.58 | $3.09 |
| P/E Ratio | $3.87 | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $4.35 | $4.46 |
| 52 Week High | $10.90 | $18.67 |
| Indicator | FINV | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 45.28 | 68.05 |
| Support Level | $4.55 | $15.66 |
| Resistance Level | $5.38 | $18.26 |
| Average True Range (ATR) | 0.29 | 1.03 |
| MACD | -0.02 | 0.14 |
| Stochastic Oscillator | 33.54 | 84.94 |
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.